Searched for: in-biosketch:yes
person:heguya01
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, Eli L; Durham, Benjamin H; Haroche, Julien; Yao, Zhan; Ma, Jing; Parikh, Sameer A; Wang, Zhaoming; Choi, John; Kim, Eunhee; Cohen-Aubart, Fleur; Lee, Stanley Chun-Wei; Gao, Yijun; Micol, Jean-Baptiste; Campbell, Patrick; Walsh, Michael P; Sylvester, Brooke; Dolgalev, Igor; Aminova, Olga; Heguy, Adriana; Zappile, Paul; Nakitandwe, Joy; Ganzel, Chezi; Dalton, James D; Ellison, David W; Estrada-Veras, Juvianee; Lacouture, Mario; Gahl, William A; Stephens, Philip J; Miller, Vincent A; Ross, Jeffrey S; Ali, Siraj M; Briggs, Samuel R; Fasan, Omotayo; Block, Jared; Heritier, Sebastien; Donadieu, Jean; Solit, David B; Hyman, David M; Baselga, Jose; Janku, Filip; Taylor, Barry S; Park, Christopher Y; Amoura, Zahir; Dogan, Ahmet; Emile, Jean-Francois; Rosen, Neal; Gruber, Tanja A; Abdel-Wahab, Omar
Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans Cell (LCH) and non-Langerhans (non-LCH) histiocytoses, respectively. The discovery of BRAFV600E mutations in ~50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of BRAFV600E-wildtype, non-LCH patients are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in BRAFV600E-wildtype, non-LCH patients. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of MAP2K1- and ARAF-mutated, non-LCH patients using MEK and RAF inhibitors, respectively, resulted in clinical efficacy demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders.
PMCID:4744547
PMID: 26566875
ISSN: 2159-8290
CID: 1834902
Advancing methylation profiling in neuropathology: Diagnosis and clinical management [Meeting Abstract]
Kannan, Kasthuri S; Tsirigos, Aristotelis; Serrano, Jonathan; Forrester, Lynn Ann; Faustin, Arline; Thomas, Cheddhi; Capper, David; Hovestadt, Volker; Pfister, Stefan M; Jones, David TW; Sill, Martin; Schrimpf, Daniel; von Deimling, Andreas; Heguy, Adriana; Gardner, Sharon L; Allen, Jeffrey; Hedvat, Cyrus; Zagzag, David; Snuderl, Matija; Karajannis, Matthias A
ISI:000369082700032
ISSN: 1557-3265
CID: 2687512
Huntington's Disease Protein Huntingtin Associates with its own mRNA
Culver, Brady P; DeClercq, Josh; Dolgalev, Igor; Yu, Man Shan; Ma, Bin; Heguy, Adriana; Tanese, Naoko
BACKGROUND: The Huntington's disease (HD) protein huntingtin (Htt) plays a role in multiple cellular pathways. Deregulation of one or more of these pathways by the mutant Htt protein have been suggested to contribute to the disease pathogenesis. Our recent discovery-based proteomics studies have uncovered RNA binding proteins and translation factors associated with the endogenous Htt protein purified from mouse brains, suggesting a potential new role for Htt in RNA transport and translation. OBJECTIVE: To investigate how Htt might affect RNA metabolism we set out to purify and analyze RNA associated with Htt. METHODS: RNA was extracted from immunopurified Htt-containing protein complexes and analyzed by microarrays and RNA-Seq. RESULTS: Surprisingly the most enriched mRNA that co-purified with Htt was Htt mRNA itself. The association of Htt protein and Htt mRNA was detected independent of intact ribosomes suggesting that it is not an RNA undergoing translation. Furthermore, we identified the recently reported mis-spliced Htt mRNA encoding a truncated protein comprised of exon 1 and a portion of the downstream intron in the immunoprecipitates containing mutant Htt protein. We show that Htt protein co-localizes with Htt mRNA and that wild-type Htt reduces expression of a reporter construct harboring the Htt 3' UTR. CONCLUSIONS: HD protein is found in a complex with its own mRNA and RNA binding proteins and translation factors. Htt may be involved in modulating its expression through post-transcriptional pathways. It is possible that Htt shares mechanistic properties similar to RNA binding proteins such as TDP-43 and FUS implicated in other neurodegenerative diseases.
PMCID:4927879
PMID: 26891106
ISSN: 1879-6400
CID: 1949822
Why do mutant allele frequencies in oncogenes peak around .40 and rapidly decrease?
Kannan, Kasthuri; Heguy, Adriana
The mutant allele frequencies in oncogenes peak around .40 and rapidly decrease. In this article, we explain why this is the case. Invoking a key result from mathematical analysis in our model, namely, the inverse function theorem, we estimate the selection coefficients of the mutant alleles as a function of germline allele frequencies. Under complete dominance of oncogenic mutations, this selection function is expected to be linearly correlated with the distribution of the mutant alleles. We demonstrate that this is the case by investigating the allele frequencies of mutations in oncogenes across various cancer types, validating our model for mean effective selection. Consistent with the population genetics model of fitness, the selection function fits a gamma-distribution curve that accurately describes the trend of the mutant allele frequencies. While existing equations for selection explain evolution at low allele frequencies, our equations are general formulas for natural selection under complete dominance operating at all frequencies. We show that selection exhibits linear behaviour at all times, favouring dominant alleles with respect to the change in recessive allele frequencies. Also, these equations show, selection behaves like power law against the recessive alleles at low dominant allele frequencies
ORIGINAL:0012234
ISSN: 2373-7867
CID: 2688922
Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target. [Meeting Abstract]
Weiss, Sarah Ann; Martinez, Carlos N.; de Miera, Eleazar Vega-Saenz; Dolgalev, Igor; Shapiro, Richard L.; Heguy, Adriana; Hernando, Eva; Kirchhoff, Tomas; Osman, Iman
ISI:000404711507146
ISSN: 0732-183x
CID: 5236632
Targeted next-generation sequencing of melanoma patient samples to reveal mutations in non-protein coding regions of targetable oncogenes. [Meeting Abstract]
Hanniford, Doug; Martinez, Carlos N.; Dolgalev, Igor; de Miera, Eleazar Vega-Saenz; Robinson, Eric Michael; Goldman, Chloe; Heguy, Adriana; Kirchhoff, Tomas; Osman, Iman; Hernando, Eva
ISI:000404711507181
ISSN: 0732-183x
CID: 5236642
Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid
Castells, Xavier; Karanovic, Sandra; Ardin, Maude; Tomic, Karla; Xylinas, Evanguelos; Durand, Geoffroy; Villar, Stephanie; Forey, Nathalie; Le Calvez-Kelm, Florence; Voegele, Catherine; Karlovic, Kresimir; Misic, Maja; Dittrich, Damir; Dolgalev, Igor; McKay, James D; Shariat, Shahrokh F; Sidorenko, Viktoria S; Fernandes, Andrea; Heguy, Adriana; Dickman, Kathleen G; Olivier, Magali; Grollman, Arthur P; Jelakovic, Bojan; Zavadil, Jiri
BACKGROUND: Dietary exposure to cytotoxic and carcinogenic aristolochic acid (AA) causes severe nephropathy typically associated with urological cancers. Monitoring of AA exposure uses biomarkers such as aristolactam-DNA adducts, detected by mass spectrometry in the kidney cortex, or the somatic A>T transversion pattern characteristic of exposure to AA, as revealed by previous DNA sequencing studies using fresh frozen tumors. METHODS: Here we report a low-coverage whole-exome sequencing method (LC-WES) optimized for multi-sample detection of the AA mutational signature, and demonstrate its utility in 17 formalin-fixed paraffin-embedded urothelial tumors obtained from 15 patients with endemic nephropathy, an environmental form of aristolochic acid nephropathy. RESULTS: LC-WES identified the AA signature, alongside signatures of age and APOBEC enzyme activity, in 15 samples sequenced at the average per-base coverage of ~10x. Analysis at 3-9x coverage revealed the signature in 91% of the positive samples. The exome-wide distribution of the predominant A>T transversions exhibited a stochastic pattern whereas 83 cancer driver genes were enriched for recurrent non-synonymous A>T mutations. In two patients, pairs of tumors from different parts of the urinary tract, including the bladder, harbored overlapping mutation patterns, suggesting tumor dissemination via cell seeding. CONCLUSION: LC-WES analysis of archived tumor tissues is a reliable method applicable to investigations of both the exposure to AA and its biological impact in human carcinomas. IMPACT: By detecting cancers associated with AA exposure in high-risk populations, LC-WES can support future molecular epidemiology studies and provide evidence-base for relevant preventive measures.
PMCID:4806408
PMID: 26383547
ISSN: 1538-7755
CID: 1779402
Improving Molecular Diagnostics with 450K Methylation Array in Clinical Neuropathology [Meeting Abstract]
Serrano, J; Forrester, L; Kannan, K; Faustin, A; Thomas, C; Capper, D; Hovestadt, V; Pfister, S; Jones, D; Sill, M; Schrimpf, D; von Deimling, A; Heguy, A; Gardner, SL; Allen, J; Tsirigos, A; Hedvat, C
ISI:000363830000273
ISSN: 1943-7811
CID: 2688362
NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition
Garcia-Rendueles, Maria E R; Ricarte-Filho, Julio C; Untch, Brian R; Landa, Inigo; Knauf, Jeffrey A; Voza, Francesca; Smith, Vicki E; Ganly, Ian; Taylor, Barry S; Persaud, Yogindra; Oler, Gisele; Fang, Yuqiang; Jhanwar, Suresh C; Viale, Agnes; Heguy, Adriana; Huberman, Kety H; Giancotti, Filippo; Ghossein, Ronald; Fagin, James A
Ch22q LOH is preferentially associated with RAS mutations in papillary and in poorly differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2, encoding merlin, is implicated in this interaction because of its frequent loss of function in human thyroid cancer cell lines. Nf2 deletion or Hras mutation are insufficient for transformation, whereas their combined disruption leads to murine PDTC with increased MAPK signaling. Merlin loss induces RAS signaling in part through inactivation of Hippo, which activates a YAP-TEAD transcriptional program. We find that the three RAS genes are themselves YAP-TEAD1 transcriptional targets, providing a novel mechanism of promotion of RAS-induced tumorigenesis. Moreover, pharmacological disruption of YAP-TEAD with verteporfin blocks RAS transcription and signaling, and inhibits cell growth. The increased MAPK output generated by NF2 loss in RAS-mutant cancers may inform therapeutic strategies, as it generates greater dependency on the MAPK pathway for viability. SIGNIFICANCE: Intensification of mutant Ras signaling through copy-number imbalances is commonly associated with transformation. We show that NF2/merlin inactivation augments mutant RAS signaling by promoting YAP/TEAD-driven transcription of oncogenic and wild-type RAS, resulting in greater MAPK output and increased sensitivity to MEK inhibitors.
PMCID:4642441
PMID: 26359368
ISSN: 2159-8290
CID: 1772832
Rare variants in the neurotrophin signaling pathway implicated in schizophrenia risk
Kranz, Thorsten M; Goetz, Ray R; Walsh-Messinger, Julie; Goetz, Deborah; Antonius, Daniel; Dolgalev, Igor; Heguy, Adriana; Seandel, Marco; Malaspina, Dolores; Chao, Moses V
Multiple lines of evidence corroborate impaired signaling pathways as relevant to the underpinnings of schizophrenia. There has been an interest in neurotrophins, since they are crucial mediators of neurodevelopment and in synaptic connectivity in the adult brain. Neurotrophins and their receptors demonstrate aberrant expression patterns in cortical areas for schizophrenia cases in comparison to control subjects. There is little known about the contribution of neurotrophin genes in psychiatric disorders. To begin to address this issue, we conducted high-coverage targeted exome capture in a subset of neurotrophin genes in 48 comprehensively characterized cases with schizophrenia-related psychosis. We herein report rare missense polymorphisms and novel missense mutations in neurotrophin receptor signaling pathway genes. Furthermore, we observed that several genes have a higher propensity to harbor missense coding variants than others. Based on this initial analysis we suggest that rare variants and missense mutations in neurotrophin genes might represent genetic contributions involved across psychiatric disorders.
PMCID:4591185
PMID: 26215504
ISSN: 1573-2509
CID: 1698442